JAJohn N. Aucott

John N. Aucott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John N. Aucott has a total of 216 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiplex single-tier LymeSeek test improves sensitivity during the diagnostic gray zone of early Lyme disease

    by Holly Ahern, James Kirk, Phillip Stafford, Nikos Tsolakos, Mara Mandelia, Elizabeth J. Horn, Alison Rebman, John Aucott, Monica E. Embers

    Lyme disease, caused by the spirochete Borrelia burgdorferi , is the most common vector-borne disease in the U.S. and a growing public health concern due to the clinically challenging nature of the disease. Prompt antibiotic treatment early in the infection results in the best patient outcomes, while delayed treatment increases the risk of developing debilitating chronic symptoms. Because standard-of-care diagnostic tests (standardized and modified two-tier tests) have low sensitivity during the first few weeks of infection, current recommendations for diagnosing early Lyme disease rely heavily on observation and recognition of erythema migrans (EM). However, a significant proportion of Lyme disease patients develop an atypical-appearing rash, or no rash is observed. To improve diagnostic accuracy, we developed LymeSeek, a microbead-based multiplex flow immunoassay performed as a single test that detects binding of IgM and IgG antibodies to a novel combination of eight B. burgdorferi antigens. Fluorescent signals from bound antibodies are translated into a disease probability and a single test result—either detected or not detected. Overall test sensitivity across all disease stages was over 90%, with no loss of specificity. The LymeSeek test performed well in blinded panels, correctly differentiating serologically positive cases from both disease and non-disease controls. The test also identified early Lyme disease cases, with and without an observed EM rash, that were negative on the current standard-of-care two-tier serological tests. The LymeSeek test has the potential to increase diagnostic accuracy and improve patient outcomes, particularly during the diagnostic gray zone of early Lyme disease. IMPORTANCE: Standard and modified two-tier serological tests for Lyme disease are not sensitive enough to diagnose patients within the first few weeks of infection, when antibiotic treatment is recognized as being most effective. This report describes a single-tier multiplex immunoassay that utilizes detection of 16 diagnostic antibodies against eight Borrelia antigens and interpretation by a machine learning-developed algorithm that demonstrates sensitivity high enough to accurately diagnose over 90% of Lyme disease cases, including those in the early diagnostic gray zone period when diagnostic uncertainty is highest. Specificity is high enough to eliminate the need for a second-tier test.

  • Open Access

    Borrelia burgdorferi disrupts gut barrier functions and microbiota–antibody interactions

    by Shilpa Sachan, Giang Vu Vi Tran, Kimberly J. Olsen, Heather Kulaga, Anne Day, Hannah P. Savage, Alison W. Rebman, John N. Aucott, Isabel A. Jimenez, Cory F. Brayton, et al.

    Lyme disease, an emerging tickborne disease caused by Borrelia burgdorferi (Bb), can result in myriad symptoms of unknown causes in humans. Here, we show that Bb rapidly disrupts the gastrointestinal immune barrier in infected mice, inducing a “leaky gut” syndrome, characterized by increased gut permeability, systemic endotoxemia, elevated LPS binding protein and intestinal fatty acid binding protein, and altered blood leukocyte profiles. Patients with acute Lyme disease showed similar blood changes that correlated with disease symptoms and liver function measurements and largely resolved after antibiotic treatment. Mechanistically, Bb infection triggered mild early inflammation in the small intestine and suppressed humoral immunity to the microbiota, resulting in reduced IgA coating of fecal microbes and decreased antimicrobial serum IgG, despite the increased gut permeability. These defects preceded shifts in later observed gut bacterial composition and short-chain fatty acid production. Together, our findings identify mucosal barrier dysfunction and impaired antimicrobial humoral immunity as potential drivers of Bb-induced disease.

  • Open Access

    Lyme disease incidence in the United States, 2016-2023

    by Sheryl A. Kluberg, Sarah J. Willis, June O’Neill, Katherine Shapiro, Kevin Coughlin, Diane Emerton, Edward Rosen, Robert Jin, John Aucott, Kimberly Daniels, et al.

    Traditional surveillance underestimates Lyme disease (LD) incidence in the United States (US). We aimed to estimate national LD incidence using validated algorithms to identify LD cases in administrative claims data. We identified potential LD cases in commercial and Medicare claims, classified cases by disease stage, adjusted case counts using algorithm-specific positive predictive values, and standardized the adjusted counts to the US population. The study population included >66 million individuals per year. After adjustment and standardization, we estimated 191.7, 26.8, and 16.6 new cases per 100,000 population in high-incidence, neighboring, and low-incidence states, respectively, with 24% of cases diagnosed with disseminated disease. The relative burden of disseminated LD was highest in low-incidence states (28.6%) and increased with age. This study corroborates published estimates of national LD incidence and elucidates patterns of disease stage at diagnosis. The substantial burden of disseminated LD underscores the need for earlier detection and treatment of LD.


  • Open Access

    Antiphospholipid antibodies in acute and post-treatment Lyme disease

    by Muskan Shrestha, Anna F. Hickman, Yuelin Zhong, Audre Zvinys, Suzanne D. Vernon, John B. Miller, Alison W. Rebman, John N. Aucott, Elizabeth J. Horn, Linden T. Hu, et al.

    Acute Lyme disease is caused by a Borrelia infection and typically responds to antibiotic treatment, but post-infectious chronic symptoms are common. The precise origin of these post-treatment symptoms is unknown; dysregulation of immune responses raised during the initial infection is likely to contribute. Antilipid antibodies are associated with several autoimmune diseases and have been shown to arise in both acute and post-treatment Lyme disease. To assess the potential contribution of antilipid antibodies to Lyme disease pathology and their possible use as biomarkers of both acute and chronic disease, we performed a survey of patient sera for antilipid antibodies during and after Borrelia burgdorferi infection. Results were similar in cross-sectional and longitudinal samples drawn from two different biobanks. Three antiphospholipid antibodies were elevated during infection, with two (antiphosphatidic acid and antiphosphatidylserine) significantly elevated even at the day of diagnosis before seroconversion on conventional tests. A subset of patients with chronic symptoms is identifiable by persistent elevation in antiphosphatidylserine; these antibodies found in post-treatment Lyme disease were not found in a panel of sera from patients with look-alike autoimmune disorders. Persistent elevation in antiphosphatidylserine may drive autoimmune-like symptoms of Lyme disease in some patients and could serve as a biomarker for chronic disease. The detection of antiphospholipid antibodies induced early in infection could also improve the diagnosis of acute infections.


  • Open Access

    Pilot study of psilocybin in patients with post-treatment lyme disease

    by Albert Garcia-Romeu, Gideon P. Naudé, Alison W. Rebman, Sara So, Abigail Yaffe, Ian Geithner, Erica A. Kozero, Ting Yang, Mark J. Soloski, John N. Aucott

    Lyme disease, caused by the bacterium Borrelia burgdorferi , is the most common vector-borne disease in the United States and Europe. Although antibiotics effectively treat most cases, an estimated 10–20% of patients develop post-treatment Lyme disease (PTLD), a chronic syndrome marked by fatigue, pain, cognitive difficulties, mood disturbance, and reduced quality of life. There are no established treatments for PTLD. The serotonin 2A receptor agonist psychedelic psilocybin has recently shown potential antidepressant and anxiolytic effects in clinical trials as well as preliminary evidence for anti-inflammatory effects in animals. This open-label, single-arm pilot study evaluated the effects of psilocybin in 20 participants with well-characterized PTLD. The 8-week intervention included two psilocybin sessions (15 mg in week 4; 15 or 25 mg in week 6) with psychological support. Participants (11 women, 9 men, mean age 44, median illness duration 5.7 years) showed significant improvements in PTLD symptom burden and quality of life from study enrollment through 1-month following the second dose of psilocybin (primary endpoint), with significant benefits sustained through 6 months. At the 6-month follow-up, general PTLD symptom burden (GSQ-30) was decreased 40% from baseline ( p < .001; Cohen’s d z = − 1.22, 95% CI [− 2.12, − 0.78]), and health-related quality of life improved across both SF-36 domains, with Mental (MCS) and Physical (PCS) component scores increasing 13% ( p ≤ .013; Cohen’s d z = 0.46–0.59). Secondary outcomes assessing mood, fatigue, sleep quality, and pain also showed significant and sustained improvement through 6 months (all p ≤ .003; Cohen’s d z = 0.56–1.25). No serious adverse events (AEs) related to the study intervention occurred. The most common AEs attributed to psilocybin were transient hypertension (90%), headache (65%), tachycardia (35%), pain (20%), and fatigue (15%). Preliminary findings support that psilocybin-assisted treatment was feasible and well-tolerated among the sample. Clinical outcomes indicated potentially long-lasting benefits of psilocybin-assisted treatment, warranting further investigation for PTLD. Trial registration: ClinicalTrials.gov Identifier NCT05305105, registered 22/03/2022.


  • Open Access

    Multiplexed single-tier immunoassay for improved Lyme disease diagnosis across all disease stages

    by Phillip Stafford, Holly Ahern, John Aucott, Alison Rebman, Elizabeth J. Horn, Marianne Hathaway, Madeleine Saunders, Nicole R. Hasenkampf, Monica E. Embers

    Lyme disease is the most common vector-borne infection in North America and Europe, yet current two-tier serologic testing shows poor sensitivity during early infection when antibiotic treatment is most effective. We developed and validated a single-tier multiplex immunoassay that combines ten Borrelia burgdorferi antigens with machine-learning classification to detect antibody responses across all disease stages. A total of 364 cases were obtained, which included well characterized prospective blood samples obtained during early infection. In a cohort of samples from the Johns Hopkins University SLICE studies, the classifier identified all 30 early Lyme disease cases and their 1–3-month post-treatment follow-up samples. To assess generalizability, an independent EU laboratory synthesized the antigens de novo and a distinct 259-person cohort was evaluated on newly built assays. The classifier achieved an AUC of 0.98 in both cohorts. This single-test platform delivers quantitative serologic classification using standard clinical laboratory instrumentation, addressing critical gaps in Lyme disease diagnosis.


  • Open Access

    Use of Infrared Thermography in Visualizing Erythema Migrans

    by Natalia I Brothers, Alison Rebman, Jonathan M. Zenilman, John Aucott

    Infrared thermography (IRT) is a non-invasive imaging technology that visualizes heat patterns on the surface of the body. IRT measures deviations from baseline body temperature that correspond to areas of increased peripheral perfusion. The use of IRT in Lyme disease is novel. The present study presents three case examples and explores IRT as a tool for detecting and understanding the erythema migrans (EM) lesions in patients diagnosed with Lyme disease. Examination of these examples revealed these lesions as round or oval areas of increased heat and prominent venous drainage. IRT images are able to identify single and disseminated EM lesions. This study highlights the potential of IRT to improve EM identification.


  • Open Access

    Aberrant T-cell phenotypes in a cohort of patients with post-treatment Lyme disease

    by Alexander A. Girgis, Raffaello Cimbro, Ting Yang, Alison W. Rebman, Thelio Sewell, Daniela Villegas de Flores, Aarti Vadalia, William H. Robinson, Andrea L. Cox, Erika Darrah, et al.

    Post-treatment Lyme Disease (PTLD) is a poorly understood complication of Borrelia burgdorferi infection with significant patient morbidity. Characterized by fatigue, generalized myalgias, and cognitive impairment, PTLD symptomatology closely resembles long COVID and other post-acute infection syndromes. While prior studies suggest immune dysregulation as a factor in PTLD pathogenesis, the mechanisms underlying its heterogeneous presentation and severity remain unclear. To associate symptom burden with discrete immune phenotypes, we applied factor analysis to self-reported symptom data from 272 PTLD patients to generate patient subgroups. We then immunophenotyped peripheral blood cells of these individuals and 28 healthy controls through 19-parameter flow cytometry and cytokine profiling to associate PTLD status and the newly defined subgroups with specific immune states. Our PTLD cohort had fewer circulating CXCR5+ CD4+ naïve T cells relative to healthy controls (5.2% vs. 8.3%, Padj < 0.001). These cells were positively associated with musculoskeletal pain in PTLD participants, but not healthy controls. This and additional immunophenotypic alterations, including an increased prevalence of CXCR3+ CCR4- CCR6- CD8 T cells (43.1% vs. 25.7%, Padj < 0.01), permitted the creation of an elastic net classifier which identified PTLD with moderate efficacy (AUC 0.83). Measurement of cytokines did not reveal associations with PTLD and did not improve the performance of the model. While we could not identify immune features which distinguished all patient subgroups, we did observe a female-specific increase in central memory CD8 T cells restricted to one high-fatigue patient subgroup. Additionally, factor analysis revealed multiple associations between immune cell frequency and the severity of specific symptoms. Collectively, our findings add to growing evidence of immune dysfunction as a prominent feature of PTLD.


  • Open Access

    Early brain changes in Lyme disease are associated with clinical outcomes

    by Cherie L. Marvel, Alison W. Rebman, Kylie H. Alm, Pegah Touradji, Arnold Bakker, Prianca A. Nadkarni, Deeya Bhattacharya, Owen P. Morgan, Amy Mistri, Christopher C. Sandino, et al.

    Lyme disease (LD) is a tick-borne infection due to the bacteria Borrelia burgdorferi. After antibiotic treatment, 10-20% of patients develop post-treatment Lyme disease (PTLD). Neurological symptoms are commonly reported in PTLD. This case-control study tested the hypothesis that brain changes occur in LD and are related to clinical outcomes. A working memory task was administered during functional MRI (fMRI), in conjunction with cognitive assessments and health surveys, to examine brain function and clinical outcomes in people with acute LD disease (n=20; 55.0% male; mean age (range) = 52.3 (26-78)). Assessments were conducted a mean of 15.2 days (range: 1-51) after initial antibiotic treatment [i.e., “baseline”] and again 6 months later. A well-matched group of healthy controls (HC, n=19; 31.6% male; mean age (range) = 46.5 (19-60)) was also assessed 6 months apart. At the 6-month follow-up, the LD group was categorized into those who returned to health (RTH, n=11) and those reporting persistent symptoms (sPTLD, n=9) to determine if early brain changes predicted subsequent outcomes. FMRI data from both LD groups were compared to the HC group. Regions of interest (ROI) values were obtained from the fMRI results and correlated to cognitive performance and symptom survey scores. At baseline, brain activity in the RTH group was significantly increased relative to that of HC. Notably, 64% of the RTH group’s activation clusters were in white matter, confirmed by segmentation analysis. ROIs created from the RTH vs. HC fMRI results, including white matter regions, significantly correlated with better self-reported clinical outcomes. At the 6-month follow-up, most of the RTH group’s activity had normalized relative to HC, and associations between ROI values and clinical outcomes were no longer observed. The sPTLD group showed few fMRI activation differences versus the HC group at either time point, and no significant associations were observed between ROI values and clinical outcomes. Instead, the sPTLD group’s ROI values negatively correlated with cognitive performance at the 6-month follow-up. These results indicate that early brain changes in LD predict future RTH status. Increased brain activation during cognition, including in white matter, may reflect a healing response without which LD patients are more likely to develop PTLD. The observed increased activation in white matter suggests specific mechanisms, such as appropriate astrocyte reactivity, and require further investigation. Understanding how increased brain activity relates to RTH in LD will aid early identification of those vulnerable to developing PTLD and guide treatment.